News

Faricimab for wet AMD effective at 16-week intervals

Genentech has announced positive topline results from its Phase III studies, TENAYA and LUCERNE, evaluating its new drug faricimab, for people with wet (neovascular) age-related macular degeneration (nAMD). Both studies have shown that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes as effective as those receiving [Read More]

Looking Forward to 2021

Even the most optimistic person will admit that 2020 was a 365-day slog through dangers, disasters, and disappointments. In a year that offered little relief, considering that its famous number might have been expected to boost our spirits with good news about vision. And that’s why it might help us to look ahead at some [Read More]

Dry Eye and Dry Macular Degeneration Are Different Conditions

Some people are confusing the eye conditions called “dry eye disease” and “dry age-related macular degeneration” (dry AMD). The confusion is understandable, but the two conditions are nothing alike.  Dry eye disease occurs when tears are not sufficient enough to provide necessary lubrication for the eyes. This problem can lead to inflammation and damage of [Read More]